Short Interest in FibroGen, Inc. (NASDAQ:FGEN) Decreases By 7.1%

FibroGen, Inc. (NASDAQ:FGEN) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 5,120,000 shares, a decrease of 7.1% from the August 15th total of 5,510,000 shares. Based on an average trading volume of 2,220,000 shares, the days-to-cover ratio is presently 2.3 days.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Alpine Global Management LLC bought a new position in shares of FibroGen during the first quarter worth $25,000. Delap Wealth Advisory LLC bought a new position in FibroGen during the first quarter worth about $27,000. Point72 DIFC Ltd lifted its holdings in FibroGen by 734.2% during the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 45,990 shares in the last quarter. Doheny Asset Management CA bought a new stake in shares of FibroGen in the second quarter worth about $48,000. Finally, Accel Wealth Management lifted its holdings in shares of FibroGen by 117.5% during the 2nd quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 51,645 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. StockNews.com started coverage on FibroGen in a report on Wednesday, September 11th. They set a “hold” rating on the stock. William Blair reissued a “market perform” rating on shares of FibroGen in a report on Monday, June 3rd.

FibroGen Stock Performance

Shares of FGEN opened at $0.45 on Wednesday. The firm has a market capitalization of $44.57 million, a price-to-earnings ratio of -0.18 and a beta of 0.69. FibroGen has a 52 week low of $0.33 and a 52 week high of $2.93. The business’s fifty day moving average price is $0.62 and its two-hundred day moving average price is $1.12.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $50.64 million during the quarter, compared to analyst estimates of $33.00 million. During the same quarter in the previous year, the business earned ($0.65) earnings per share. As a group, research analysts forecast that FibroGen will post -0.91 EPS for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.